Cargando…

microRNAs and next generation sequencing for the prognosis of the metastatic melanoma

Detalles Bibliográficos
Autores principales:	Pinto, Rosamaria, De Summa, Simona, Strippoli, Sabino, Guida, Gabriella, Popescu, Ondina, Azzariti, Amalia, Guida, Michele, Tommasi, Stefania
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315284/ http://dx.doi.org/10.1186/1479-5876-13-S1-P4

Ejemplares similares

The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy response
por: Pinto, Rosamaria, et al.
Publicado: (2016)

Proteomic Profile and In Silico Analysis in Metastatic Melanoma with and without BRAF Mutation
por: Garrisi, Vito Michele, et al.
Publicado: (2014)

The Genetic Germline Background of Single and Multiple Primary Melanomas
por: De Summa, Simona, et al.
Publicado: (2021)

The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale)
por: Guida, Michele, et al.
Publicado: (2018)

Genetic profiling of a rare condition: co-occurrence of albinism and multiple primary melanoma in a caucasian family
por: De Summa, Simona, et al.
Publicado: (2016)

Barasertib: a novel approach for the treatment of metastatic melanoma
por: Azzariti, Amalia, et al.
Publicado: (2014)

The relevance of BRAF G469A mutation in determining the response to therapy in metastatic melanoma
por: Porcelli, Letizia, et al.
Publicado: (2015)

Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy
por: Porcelli, Letizia, et al.
Publicado: (2015)

Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
por: Serratì, Simona, et al.
Publicado: (2022)

Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma
por: Serratì, Simona, et al.
Publicado: (2023)

Tomatine Displays Antitumor Potential in In Vitro Models of Metastatic Melanoma
por: Serratì, Simona, et al.
Publicado: (2020)

uPAR(+) extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients
por: Porcelli, Letizia, et al.
Publicado: (2021)

miRNAs as Key Players in the Management of Cutaneous Melanoma
por: Lorusso, Celeste, et al.
Publicado: (2020)

Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients
por: Danza, Katia, et al.
Publicado: (2014)

The mitochondrial master regulator gene PGC1alpha in novel sporadic melanoma cell lines: correlations with BRAF mutational status
por: Guida, Gabriella, et al.
Publicado: (2014)

Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?
por: Schirosi, Laura, et al.
Publicado: (2016)

Translational control mechanisms in cutaneous malignant melanoma: the role of eIF2α
por: Maida, Immacolata, et al.
Publicado: (2019)

TGFbeta and miRNA regulation in familial and sporadic breast cancer
por: Danza, Katia, et al.
Publicado: (2017)

Next-generation sequencing: advances and applications in cancer diagnosis
por: Serratì, Simona, et al.
Publicado: (2016)

GATK hard filtering: tunable parameters to improve variant calling for next generation sequencing targeted gene panel data
por: De Summa, Simona, et al.
Publicado: (2017)

The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma
por: Guida, Michele, et al.
Publicado: (2019)

Immunoprofile from tissue microarrays to stratify familial breast cancer patients
por: Schirosi, Laura, et al.
Publicado: (2015)

Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells
por: Azzariti, Amalia, et al.
Publicado: (2019)

The β-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study
por: Porcelli, Letizia, et al.
Publicado: (2020)

The ERRα–VDR axis promotes calcitriol degradation and estrogen signaling in breast cancer cells, while VDR‐CYP24A1‐ERRα overexpression correlates with poor prognosis in patients with basal‐like breast cancer
por: Danza, Katia, et al.
Publicado: (2021)

Behind the Scene: Exploiting MC1R in Skin Cancer Risk and Prevention
por: Manganelli, Michele, et al.
Publicado: (2021)

Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study
por: Guida, M., et al.
Publicado: (2021)

The Role of Non-Coding RNAs as Prognostic Factor, Predictor of Drug Response or Resistance and Pharmacological Targets, in the Cutaneous Squamous Cell Carcinoma
por: Garofoli, Marianna, et al.
Publicado: (2020)

Long Non-Coding RNA Landscape in Prostate Cancer Molecular Subtypes: A Feature Selection Approach
por: De Summa, Simona, et al.
Publicado: (2021)

Cervical cancer benefits from trabectedin combination with the β-blocker propranolol: in vitro and ex vivo evaluations in patient-derived organoids
por: Di Fonte, Roberta, et al.
Publicado: (2023)

Identification of differentially expressed microRNAs in metastatic melanoma using next-generation sequencing technology
por: QI, MIN, et al.
Publicado: (2014)

Cellular analysis of bronchoalveolar lavage fluid to narrow differential diagnosis of checkpoint inhibitor-related pneumonitis in metastatic melanoma
por: Strippoli, Sabino, et al.
Publicado: (2020)

miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype
por: Tommasi, Stefania, et al.
Publicado: (2016)

MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis
por: Danza, Katia, et al.
Publicado: (2014)

αβ-Double Negative CD4/CD8 (CD56) T cell (DNTs) in metastatic melanoma: basal frequency and behaviour during Ipilimumab treatment. Preliminary evaluations
por: De Tullio, Giacoma, et al.
Publicado: (2015)

MicroRNA expression profiling in male and female familial breast cancer
por: Pinto, R, et al.
Publicado: (2014)

Electrochemotherapy as a Trigger to Overcome Primary Resistance to Anti-PD-1 Treatment: A Case Report of Melanoma of the Scalp
por: Quaresmini, Davide, et al.
Publicado: (2021)

Herbal-drug interaction induced rhabdomyolysis in a liposarcoma patient receiving trabectedin
por: Strippoli, Sabino, et al.
Publicado: (2013)

Melanoma Brain Metastases: A Retrospective Analysis of Prognostic Factors and Efficacy of Multimodal Therapies
por: Internò, Valeria, et al.
Publicado: (2023)

Examining the Relationship between Circulating CD4− CD8− Double-Negative T Cells and Outcomes of Immuno-Checkpoint Inhibitor Therapy—Looking for Biomarkers and Therapeutic Targets in Metastatic Melanoma
por: Strippoli, Sabino, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j29hjjftdihmgpd30r06lplhjp